Pear
Therapeutics, Inc., the leader in prescription digital therapeutics
(PDTs), today announced poster and oral presentations for the American
Psychiatric Association Annual Meeting May 18-22 in San Francisco. The
presentations will include clinical trial data for reSET, for the
treatment of Substance Use Disorder, and Pear-004, for the treatment of
Schizophrenia.
“Prescription digital therapeutics are a novel treatment class in
healthcare that represent a shift in how we treat serious disease,
delivering efficacy for enhanced outcomes as part of standard of care
while simultaneously empowering people to access care as they need it,”
said Yuri Maricich, M.D., M.B.A., Chief Medical Officer at Pear
Therapeutics. “While prescription digital therapeutics deliver
scientific mechanisms of action and undergo rigorous testing via
randomized clinical trials and review by regulatory bodies such as the
FDA, there is a need to educate healthcare providers and patients on the
difference between PDTs and unregulated health and wellness apps.”
Dr. Maricich will deliver a podium presentation titled, “Prescription
Digital Therapeutics: A New Addition to Standard of Care,” on
Monday, May 20 at 12:00 p.m. PT. The session will include presentations
and a panel discussion featuring:
John Santopietro, M.D., DFAPA, Senior Vice President, Hartford
HealthCare; Physician–In–Chief, Behavioral Health Network; Assistant
Clinical Professor of Psychiatry, Yale School of Medicine; Assistant
Professor of Psychiatry, University of Connecticut School of Medicine
Tim
Campellone, Ph.D., Clinical Director, Multiple Sclerosis, Pear
Therapeutics
Frances Thorndike, Ph.D., Global Clinical Lead,
Insomnia, Pear Therapeutics
Ken Weingardt, Ph.D., Clinical
Director, Schizophrenia, Pear Therapeutics
In addition, Pear will present two scientific posters:
Early Prediction of High-Risk Patients Is an Opportunity for Early
Intervention (poster number P6-010) will be
featured Monday, May 20 from 2:00 – 4:00 p.m. PT. The poster highlights
data demonstrating the ability to predict with 70% accuracy whether
people are likely to complete treatment with reSET based on engagement
data from the first week of treatment, providing the potential to better
identify and treat high-risk patients.
Agile Development of Pear-004, a Prescription Digital Therapeutic
for Patients With Schizophrenia (poster number P7-029) will be
featured Tuesday, May 21 from 10:00 a.m. to 12:00 p.m. PT. The poster
highlights the iterative nature of PDT development, often involving
extensive clinician and patient feedback, and multiple product
iterations to enhance engagement, dosing, and efficacy. Pear-004 is
currently in a phase
2 proof-of-concept study in collaboration with Novartis.
Pear Therapeutics is a privately held, prescription digital therapeutics
company developing clinically validated, FDA-authorized software
applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the
leader in prescription digital therapeutics. We aim to redefine medicine
by discovering, developing, and delivering clinically validated
software-based therapeutics to provide better outcomes for patients,
smarter engagement and tracking tools for clinicians, and cost-effective
solutions for payers. Pear has a pipeline of products and product
candidates across therapeutic areas, including severe psychiatric and
neurological conditions. Our lead product, reSET®, treats
Substance Use Disorder and was the first prescription digital
therapeutic to receive marketing authorization from the FDA to treat
disease. Pear’s second product, reSET-O®, for the treatment
of Opioid Use Disorder, received marketing authorization from the FDA in
December 2018. For more information, visit us at www.peartherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190518005001/en/